Pathological variants in TOP3A cause distinct disorders of mitochondrial and nuclear genome stability.


Journal

EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380

Informations de publication

Date de publication:
08 05 2023
Historique:
revised: 10 03 2023
received: 19 08 2022
accepted: 14 03 2023
medline: 9 5 2023
pubmed: 5 4 2023
entrez: 4 4 2023
Statut: ppublish

Résumé

Topoisomerase 3α (TOP3A) is an enzyme that removes torsional strain and interlinks between DNA molecules. TOP3A localises to both the nucleus and mitochondria, with the two isoforms playing specialised roles in DNA recombination and replication respectively. Pathogenic variants in TOP3A can cause a disorder similar to Bloom syndrome, which results from bi-allelic pathogenic variants in BLM, encoding a nuclear-binding partner of TOP3A. In this work, we describe 11 individuals from 9 families with an adult-onset mitochondrial disease resulting from bi-allelic TOP3A gene variants. The majority of patients have a consistent clinical phenotype characterised by bilateral ptosis, ophthalmoplegia, myopathy and axonal sensory-motor neuropathy. We present a comprehensive characterisation of the effect of TOP3A variants, from individuals with mitochondrial disease and Bloom-like syndrome, upon mtDNA maintenance and different aspects of enzyme function. Based on these results, we suggest a model whereby the overall severity of the TOP3A catalytic defect determines the clinical outcome, with milder variants causing adult-onset mitochondrial disease and more severe variants causing a Bloom-like syndrome with mitochondrial dysfunction in childhood.

Identifiants

pubmed: 37013609
doi: 10.15252/emmm.202216775
pmc: PMC10165364
doi:

Substances chimiques

DNA, Mitochondrial 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e16775

Subventions

Organisme : Medical Research Council
ID : MR/S005021/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/W019027/1
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom

Informations de copyright

© 2023 The Authors. Published under the terms of the CC BY 4.0 license.

Références

Nat Rev Mol Cell Biol. 2011 Nov 23;12(12):827-41
pubmed: 22108601
Nucleic Acids Res. 2020 May 7;48(8):4448-4462
pubmed: 32232337
Clin Genet. 2023 Apr;103(4):492-494
pubmed: 36544354
Nucleic Acids Res. 2021 Jan 8;49(D1):D1541-D1547
pubmed: 33174596
Nucleic Acids Res. 1998 Sep 15;26(18):4205-13
pubmed: 9722641
Cell. 2020 Apr 2;181(1):168-188
pubmed: 32220313
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Biochim Biophys Acta Mol Basis Dis. 2021 Jun 1;1867(6):166106
pubmed: 33631320
Nucleic Acids Res. 2022 Aug 26;50(15):8733-8748
pubmed: 35904803
Nucleic Acids Res. 2012 Apr;40(7):e53
pubmed: 22241780
J Biol Chem. 2006 May 19;281(20):13861-4
pubmed: 16595695
EMBO Mol Med. 2023 May 8;15(5):e16775
pubmed: 37013609
Genes Dev. 2008 Oct 15;22(20):2843-55
pubmed: 18923082
EMBO J. 2005 Apr 6;24(7):1465-76
pubmed: 15775963
Sci Rep. 2015 Oct 15;5:15037
pubmed: 26469001
N Engl J Med. 2021 Nov 11;385(20):1868-1880
pubmed: 34758253
J Biol Chem. 2005 Feb 4;280(5):3564-73
pubmed: 15537633
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Molecules. 2018 Sep 05;23(9):
pubmed: 30189687
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6228-33
pubmed: 20308575
PLoS Genet. 2020 Dec 14;16(12):e1009242
pubmed: 33315859
Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1010-3
pubmed: 9448276
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12114-9
pubmed: 12209014
Nature. 1989 May 25;339(6222):309-11
pubmed: 2725645
Mol Cell. 2012 Sep 28;47(6):886-96
pubmed: 22885009
Nat Struct Mol Biol. 2019 Apr;26(4):267-274
pubmed: 30936532
J Biomed Sci. 2016 Apr 12;23:38
pubmed: 27067525
J Mol Biol. 2007 Apr 20;368(1):105-18
pubmed: 17331537
Nat Commun. 2019 Feb 15;10(1):759
pubmed: 30770810
Cell. 1995 Nov 17;83(4):655-66
pubmed: 7585968
Sci Rep. 2017 Aug 17;7(1):8614
pubmed: 28819183
Nat Genet. 2001 Jul;28(3):223-31
pubmed: 11431692
Cell. 2009 Aug 21;138(4):628-44
pubmed: 19703392
Nucleic Acids Res. 2022 Oct 28;50(19):11154-11174
pubmed: 36215039
Genome Res. 2011 Mar;21(3):487-93
pubmed: 21209072
Nat Commun. 2021 Feb 18;12(1):1135
pubmed: 33602924
Genet Med. 2022 Jul;24(7):1476-1484
pubmed: 35420546
Nat Genet. 2013 Feb;45(2):214-9
pubmed: 23313956
Am J Hum Genet. 1994 Oct;55(4):760-76
pubmed: 7942855
Nucleic Acids Res. 2015 Dec 15;43(22):11031-46
pubmed: 26490962
Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3653-7
pubmed: 8622991
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
J Med Genet. 2004 Feb;41(2):e19
pubmed: 14757869
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10608-13
pubmed: 11526219
Am J Hum Genet. 2013 Feb 7;92(2):293-300
pubmed: 23352259
Nucleic Acids Res. 2014 Jan;42(2):1111-6
pubmed: 24163253
Am J Hum Genet. 2018 Sep 6;103(3):456
pubmed: 30193137
Nat Genet. 2001 Jul;28(3):211-2
pubmed: 11431686
Neurology. 1995 Apr;45(4):762-8
pubmed: 7723967
Genes Dev. 2008 Oct 15;22(20):2856-68
pubmed: 18923083
Annu Rev Biochem. 2016 Jun 2;85:133-60
pubmed: 27023847
J Biol Chem. 2000 Mar 31;275(13):9636-44
pubmed: 10734115
Am J Hum Genet. 2015 Jul 2;97(1):186-93
pubmed: 26094573
BMJ. 2018 Apr 24;361:k1687
pubmed: 29691228
Nat Struct Mol Biol. 2014 Mar;21(3):261-8
pubmed: 24509834
Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4068-73
pubmed: 16537486
Nat Rev Dis Primers. 2016 Oct 20;2:16080
pubmed: 27775730
Neurol Genet. 2022 Jul 6;8(4):e200007
pubmed: 35812164
J Biol Chem. 2020 May 15;295(20):7138-7153
pubmed: 32277049
Mol Cell. 2018 Jan 4;69(1):9-23.e6
pubmed: 29290614
Histochem J. 1989 Sep-Oct;21(9-10):545-55
pubmed: 2556354
Nat Genet. 1993 May;4(1):67-71
pubmed: 8513327
J Biol Chem. 2010 Jul 9;285(28):21426-36
pubmed: 20445207
FEBS Lett. 2021 Apr;595(8):976-1002
pubmed: 33314045
J Biol Chem. 2007 Sep 28;282(39):28971-28979
pubmed: 17693398
Am J Hum Genet. 2006 Jun;78(6):1026-34
pubmed: 16685652

Auteurs

Direnis Erdinc (D)

Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Gothenburg, Sweden.

Alejandro Rodríguez-Luis (A)

Wellcome Centre for Mitochondrial Research, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Mahmoud R Fassad (MR)

Wellcome Centre for Mitochondrial Research, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Sarah Mackenzie (S)

The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Christopher M Watson (CM)

North East and Yorkshire Genomic Laboratory Hub, Central Lab, St. James's University Hospital, Leeds, UK.
Leeds Institute of Medical Research, University of Leeds, St. James's University Hospital, Leeds, UK.

Sebastian Valenzuela (S)

Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Gothenburg, Sweden.

Xie Xie (X)

Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Gothenburg, Sweden.

Katja E Menger (KE)

Wellcome Centre for Mitochondrial Research, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Kate Sergeant (K)

Oxford Genetics Laboratories, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Kate Craig (K)

Wellcome Centre for Mitochondrial Research, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Sila Hopton (S)

Wellcome Centre for Mitochondrial Research, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Gavin Falkous (G)

Wellcome Centre for Mitochondrial Research, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Joanna Poulton (J)

Nuffield Department of Women's & Reproductive Health, The Women's Centre, University of Oxford, Oxford, UK.

Hector Garcia-Moreno (H)

Department of Clinical and Movement Neurosciences, Ataxia Centre, UCL Queen Square Institute of Neurology, London, UK.

Paola Giunti (P)

Department of Clinical and Movement Neurosciences, Ataxia Centre, UCL Queen Square Institute of Neurology, London, UK.

Carlos A de Moura Aschoff (CA)

Medical Genetics Service, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil.

Jonas A Morales Saute (JA)

Medical Genetics Service, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil.
Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Graduate Program in Medicine: Medical Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Amelia J Kirby (AJ)

Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Camilo Toro (C)

Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.

Lynne Wolfe (L)

Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.

Danica Novacic (D)

Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.

Lior Greenbaum (L)

The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.
The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Aviva Eliyahu (A)

The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Ortal Barel (O)

Genomics Unit, The Center for Cancer Research, Sheba Medical Center, Tel Hashomer, Israel.

Yair Anikster (Y)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Metabolic Disease Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.

Robert McFarland (R)

Wellcome Centre for Mitochondrial Research, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Gráinne S Gorman (GS)

Wellcome Centre for Mitochondrial Research, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Andrew M Schaefer (AM)

Wellcome Centre for Mitochondrial Research, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Claes M Gustafsson (CM)

Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Gothenburg, Sweden.
Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden.

Robert W Taylor (RW)

Wellcome Centre for Mitochondrial Research, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Maria Falkenberg (M)

Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Gothenburg, Sweden.

Thomas J Nicholls (TJ)

Wellcome Centre for Mitochondrial Research, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH